August 5, 2026

To	To
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	**BSE LIMITED**
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25th floor, Dalal Street,
MUMBAI -400 051	**MUMBAI -400 001**
Company Code No. AUROPHARMA	**Company Code No. 524804**

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 19:48:19 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

AUROBINDO

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Hyderabad, India, August 05th, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2026.

Aurobindo Pharma Limited Q1FY27

Amount (INR Cr)	Q1FY27	Q1FY26	% Change YoY	Q4FY26	% Change QoQ
Revenue from Operations	9,150	7,868	16.3%	8,853	3.4%
EBITDA before R&D	2,208	1,947	13.4%	2,165	2.0%
EBITDA margin before R&D	24.1%	24.8%	-63 bps	24.5%	-33 bps
EBITDA (Before Forex and Other Income and exceptional items)	1,924*	1,603	20.0%	1,801	6.8%
EBITDA Margin (%)	21.0%	20.4%	60 bps	20.3%	69 bps
PBT before share of P/L of JV	1,517	1,205	25.9%	1,293	17.3%
Net Profit for the period	1,032	824	25.2%	921	12.1%

**Operating EBITDA excluding one time impact of ₹43 cr on account of derecognition of lease receivable*

Key Highlights of Q1FY27

- Revenue from Operations increased by 16.3% YoY to INR 9,150 Cr with growth across businesses
- US revenue increased by 8.1% YoY to INR 3,770 Cr (USD 399 million)
- Europe revenue increased by 25.6% YoY to INR 2,937 Cr (EUR 267 million)
- Growth Markets revenue increased by 37.7% YoY to INR 1,063 Cr (USD 113 million)
- ARV revenue for the quarter stood at INR 330 Cr (USD 35 million)
- Received final approval for 10 products from USFDA
- Net Profit for the quarter stood at INR 1,032 Cr
- Strong net cash position (including investments) stood at USD 42mn as on 30-Jun-26 (after payment of Lannett acquisition amounting to USD 247mn and buyback of USD 85mn)
- Generated free cash flow of USD 98mn during the quarter
- Basic & Diluted EPS stood at INR 17.86 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: *"We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders."*

Operational Performance (Consolidated)

₹ Cr	Q1FY27	Q1FY26	YoY (%)	Q4FY26	QoQ (%)
USA	3,770	3,488	8.1%	3,543	6.4%
Europe	2,937	2,338	25.6%	2,795	5.1%
Growth Markets*	1,063	772	37.7%	980	8.5%
ARV	330	355	-6.9%	328	0.8%
Total Formulations	**8,101**	**6,953**	**16.5%**	**7,646**	**6.0%**
Beta-lactam	800	636	25.7%	918	-12.9%
Non Beta-lactam	250	279	-10.6%	290	-13.8%
Total API	**1,049**	**916**	**14.6%**	**1,208**	**-13.1%**
Revenue from Operations	**9,150**	**7,868**	**16.3%**	**8,853**	**3.4%**

**Includes domestic sales of INR 104 Cr in Q1FY27 against INR 75 Cr in Q4FY26*

Q1FY27: Consolidated Revenue Breakup - Geography & Business Wise

Q1FY27





Q1FY27: Business Area Wise Performance

Formulations revenue increased by 16.5% YoY to INR 8,101 Cr.

US Formulations

- US revenue increased by 8.1% YoY to INR 3,770 Cr primarily driven by volume gains and new launches, partially offset by no transient product sales
- As on 30-Jun-26, on a cumulative basis, the company has filed 896 ANDAs with USFDA and has received 737 final approvals and 33 tentative approvals
- Launched 10 products during the quarter

Europe Formulations

- Europe revenue increased by 25.6% YoY to INR 2,937 Cr, driven by robust performance across all key markets; and accounted for 32.1% of consolidated revenue
- In euro terms, revenue increased by 11.0% YoY to EUR 267 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 37.7% YoY to INR 1,063 Cr, driven by strong performance across key markets; and accounted for 11.6% of consolidated revenue
- In USD terms, revenue increased by 25.0% YoY to USD 113 million
- Domestic sales for the quarter stood at INR 104 Cr

ARV Formulations

- ARV business revenue remained broadly stable at INR 330 Cr with QoQ variation driven by tender opportunities, accounting for 3.6% of consolidated revenue
- In USD terms, revenue decreased by 2.5% QoQ to USD 35 million

Active Pharmaceutical Ingredients (API)

- API revenues increased 14.6% YoY, despite sequential seasonal softness in the antibiotics portfolio, and contributed 11.5% of consolidated revenue
- In USD terms, revenue increased by 3.7% YoY to USD 111 million

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

AUROBINDO

Q1FY27: Final USFDA Approvals Received

Aurobindo Pharma Limited

#	Product	Strength	Therapy Area
1	Canagliflozin Tablets (FTF)	100 mg and 300 mg	ANTI-DIABETIC
2	Pirfenidone Capsules (FTF)	267 mg	ANTIFIBROTIC AGENT
3	Eluxadoline Tablets (FTF)	75 mg and 100 mg	ANTI-DIARRHEAL
4	Cephalexin for Oral Suspension USP	125 mg/ 5 mL and 250 mg/5 mL	ANTI-INFECTIVE
5	Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC)	30 mg/5 mL	RESPIRATORY DRUGS
6	Icosapent Ethyl Capsules	1 gram	CARDIO VASCULAR DRUGS
7	Dapagliflozin Tablets (FTF)^^	5mg and 10mg	ANTI-DIABETIC
8	Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (FTF)^^	5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg and 10 mg/1000 mg	ANTI-DIABETIC
9	Tofacitinib Tablets^^	5mg and 10mg	PAIN RELIEF DRUGS
10	Glycerol Phenylbutyrate Oral Liquid^^	1.1 grams per mL	NITROGEN-BINDING AGENT

^^ Received Tentative approval earlier now received Final approval

Q1FY27: Earnings Call Details

The company will host earnings call at **8.30 AM IST on 06-Aug-26**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: https://bit.ly/4gVr1CV

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com) , (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 19:48:42 +05'30'